Lido Advisors’s Ginkgo Bioworks DNA Stock Holding History

Lido Advisors’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-252	Closed	-$11.7K	–	1432
2024 Q1	$11.7K	Buy	+252	New	+$13K	﹤0.01%	1377

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Lido Advisors's DNA Position: Q2 2024 in Review

Lido Advisors sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 252 shares — an estimated $11.7K sold.

Lido Advisors first reported a position in DNA in Q1 2024 and held it in 1 quarter. The position peaked at $11.7K in Q1 2024. 312 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

Lido Advisors reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
Lido Advisors sold 252 Ginkgo Bioworks shares in Q2 2024, an estimated $11.7K.
Lido Advisors first reported a position in Ginkgo Bioworks in Q1 2024 and held it in 1 quarter.
Lido Advisors's Ginkgo Bioworks position peaked at $11.7K in Q1 2024.
312 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Lido Advisors's 13F filing for Q2 2024, filed 15 Aug 2024.